Stoke Therapeutics (STOK) Income towards Parent Company (2018 - 2026)

Stoke Therapeutics has reported Income towards Parent Company for 9 years, with the latest figure at -$50.0 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 144.3% year-over-year to -$50.0 million; the trailing twelve-month figure through Mar 2026 stood at -$169.7 million (down 438.83% YoY), and the FY2025 full-year result was -$6.8 million, up 92.3% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$50.0 million, up from -$57.8 million in the prior quarter.
• The five-year high for Income towards Parent Company was $112.9 million in Q1 2025, with the low at -$57.8 million in Q4 2025.
• Average Income towards Parent Company over 5 years is -$20.7 million, with a median of -$25.7 million recorded in 2022.
• Peak annual rise in Income towards Parent Company reached 527.99% in 2025, while the deepest fall reached 441.27% in 2025.
• Tracing STOK's Income towards Parent Company over 5 years: stood at -$25.7 million in 2022, then declined by 5.07% to -$27.0 million in 2023, then soared by 60.43% to -$10.7 million in 2024, then plunged by 441.27% to -$57.8 million in 2025, then gained by 13.53% to -$50.0 million in 2026.
• The last three Income towards Parent Company figures came in at -$50.0 million (Q1 2026), -$57.8 million (Q4 2025), and -$38.3 million (Q3 2025), per Business Quant data.

Peer Comparison